EN DE
Watch Blue Sail Medical Co Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Blue Sail Medical Co Ltd (002382) fair value: what the stock is really worth

As of Oct 19, 2026: fair value (intrinsic value) of Blue Sail Medical Co Ltd stock ¥4.42, price ¥6.29, upside -29.7%, quality 41 out of 100. Rating: overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · CN · ISIN CNE100000MZ7

BS Blue Sail Medical Co Ltd logo Thin data Oct 3, 2026

Blue Sail Medical Co Ltd

002382 · SHE

Weak valuationQuality is weak on top of the rich price.

Our calculation puts a fair price 30% below what the stock costs today.

Low debt
Quality 41/100
Mixed vs. peers (6/12)
Fair value ¥4.42 · Overvalued (−29.7%)
Weak Growth (revenue 5y −6.1 %/yr in CNY)
Loss-making · -8.3% net margin (TTM)
Negative free cash flow
Narrow moat 27/100
Thin data
Watch Blue Sail Medical Co Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

¥21.11 ¥4.21 Fair Value ¥4.42 May 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.

How to read this chart

60‑month range ¥4.21 – ¥21.11 · fair‑value band ¥3.02 – ¥5.82 · the ¥6.29 price screens above the ¥4.42 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 3, 2026.

Follow Blue Sail Medical Co in your weekly email

Every Wednesday you see whether Blue Sail Medical Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Blue Sail Medical Co.,Ltd. operates as a medical device company in China and internationally. It operates through Health Protection Division; Cardiovascular and Cerebrovascular Department; and Emergency Rescue Division segments.

Show moreShow less

The company offers cardiovascular and cerebrovascular products comprising drug-eluting stents and balloons, conventional balloons, and transcatheter aortic valve replacement systems; and disposable health protection gloves consisting of disposable nitrile, PVC, latex, and TPE/CPE gloves, as well as polyurethane gloves for use in medical examinations, food processing, industrial labor protection, daily protection, and other applications.

It also provides emergency rescue products, such as road rescue kits, Red Cross foreign aid kits, AED family emergency kits, Firstaid series, mother's parcels, pet and catering first aid kits, portable protection and AED emergency kits, road rescue and fire emergency kits, AED first aid kits, eye wash first aid kits, face towels, cotton soft towels, disposable bed sheets and quilts, daily underwear, mini cleansing wipes, kitchen wipes, first aid blankets, thermal insulation blankets, filter-type fire self-rescue respirators, emergency escape ropes, medical ice packs, and medical antipyretic ice patches.

In addition, the company offers nano antibody anti-corona and electronic protection sprays, nano antibody liquid masks, nasal rinsers, and sea salt water nasal sprays; and mussel mucin nasal and oral sprays.

The company was formerly known as Shandong Blue Sail Plastic & Rubber Co., Ltd. and changed its name to Blue Sail Medical Co.,Ltd. in July 2014. Blue Sail Medical Co.,Ltd. was founded in 2002 and is headquartered in Zibo, China.

Stock analysis

Blue Sail Medical Co Ltd (002382) currently trades at ¥6.29, while our model-based Fair Value estimate is ¥4.42, 29.7% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of ¥4.42 per share, and 0 of the 4 models we run sit above the ¥6.29 price.

Bear case: the Asset-Based group reads lowest at ¥1.27, and 4 of the 4 models stay below the price. Data coverage for this calculation is low.

Scenario range: ¥3.02 (bear) to ¥5.82 (bull), the price of ¥6.29 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Blue Sail Medical Co Ltd reported revenue of 5.7B CNY in FY2025 versus 8.1B CNY in FY2021, a compound −8.3%/yr. Reported net income was −759M CNY in FY2025.

Key figures

Market cap 6.3B CNY (≈ $950M) Small · P/S ratio 0.97 · EPS (TTM) ¥−0.5400 · Dividend yield 2.6% · Net margin −8.3% · Return on equity −4.9% · Return on assets (EBIT) −0.3% · Operating margin 17.2%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 27 out of 100 (medium confidence).

What moves the price

The share trades about 27% below its 52-week high and 24% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −39% fair-value upside, at −30%, 002382 screens cheaper than that median.

Fair Value models

Bear ¥3.02 Fair Value ¥4.42 Bull ¥5.82
Price ¥6.29 · Upside -29.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EV/EBITDA ¥3.02 ¥4.42 ¥5.82 67
Gordon GGM ¥1.36 ¥2.54 ¥3.60 65
DDM Multi-Stage ¥1.36 ¥2.27 ¥2.70 65
All 4 models by family
Dividend Discount
Gordon GGM ¥1.36 ¥2.54 ¥3.60 65
DDM Multi-Stage ¥1.36 ¥2.27 ¥2.70 65
Multiples
EV/EBITDA ¥3.02 ¥4.42 ¥5.82 67
Asset-Based
NCAV (Graham) ¥0.9400 ¥1.27 ¥1.89 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 41/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 6
How much profit the company makes from its sales and capital
Quality Growth 27
Are margins and returns getting better?
Cashflow 16
Do the profits arrive as real cash?
Financial strength 46
Debt, balance sheet and risk of trouble
Investment 83
Does it invest with discipline instead of growing at any price?
Low Volatility 75
How calm the share price moves, does not count
Momentum 42
Price trend of the last 3 to 12 months, does not count
Near the 52-week high 41
Distance to the 52-week high, does not count
New shares 84
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−8.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−6.1%
Start year 2020 (pandemic). Over 10 years: +14.3% a year
Revenue growth 19 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
25.9% (2020) → −2.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

002382 screens overvalued: fair value 30% below the price. Compare with Intuitive Surgical, Inc →

Compare Blue Sail Medical Co Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 184 stocks

Beats the industry median on 6/11 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 41 · Bottom 25%
Fair Value upside −29.7% · Below median
Profitability
Return on assets −4.5% · Bottom 25%
Net margin (12 months) −8.3% · Bottom 25%
Operating margin (12 months) 17.2% · Above median
Growth and dividend
Revenue growth (quarter YoY) 56.5% · Top 25%
Dividend yield (12 months) 2.6% · Above median
Balance sheet
Debt / equity 0.09× · Above median

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/B 0.88× · Cheapest 25%
P/S (12 months) 0.96× · Cheapest 25%
EV/EBITDA 6.5× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 21
FUTURE (revenue growth)100 · sector 36
PAST (return on equity)0 · sector 28
HEALTH (low debt)96 · sector 96
DIVIDEND (yield)53 · sector 33

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Solventum Corporation SOLV $87.29 $134.36 +54% vs 002382
EssilorLuxottica Société anonyme EL €148.70 €163.57 +10% vs 002382
Intuitive Surgical, Inc ISRG $420.24 $348.72 −17% vs 002382
Medline Inc MDLN $35.93 $29.06 −19% vs 002382
Alcon Inc ALC $66.18 $40.13 −39% vs 002382
Becton, Dickinson and Company BDX $191.75 $104.73 −45% vs 002382
Straumann Holding STMN CHF 93.82 CHF 45.50 −52% vs 002382
West Pharmaceutical Services, Inc WST $366.00 $137.81 −62% vs 002382
Sartorius Stedim Biotech S.A DIM €215.00 €54.82 −75% vs 002382
Baxter International Inc BAX $24.35 $2.68 −89% vs 002382

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Blue Sail Medical Co Ltd · Fair Value
¥4.42 −30%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Blue Sail Medical Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/002382

Frequently asked questions

Is Blue Sail Medical Co Ltd (002382) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of ¥4.42 versus a price of ¥6.29, about −30% upside (overvalued).
What is the fair value of 002382?
Our model-based fair value for Blue Sail Medical Co Ltd is ¥4.42 (as of Oct 3, 2026), built from audited fundamentals. The current price: ¥6.29.
What is the quality score of 002382?
Blue Sail Medical Co Ltd has a Quality Score of 41/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Blue Sail Medical Co Ltd (002382)?
Our model-based price target is the fair value of ¥4.42 (as of Oct 3, 2026) from 4 valuation models. Cautious scenario ¥3.02, optimistic scenario ¥5.82. It is a calculation from audited fundamentals, not an analyst target.
What is the Blue Sail Medical Co Ltd stock forecast for 2026?
Our models put fair value at ¥4.42, about −30% upside versus a price of ¥6.29 (overvalued). Cautious scenario ¥3.02, optimistic scenario ¥5.82. The calculation is refreshed regularly with new filings.
What is the revenue of Blue Sail Medical Co Ltd (002382)?
Blue Sail Medical Co Ltd reported trailing-twelve-month revenue of about 6.6B CNY (latest available figure, as of Oct 3, 2026).
Does Blue Sail Medical Co Ltd pay a dividend?
Blue Sail Medical Co Ltd currently shows a dividend yield of 2.65% relative to its recent price (as of Oct 3, 2026).
What is the intrinsic value of Blue Sail Medical Co Ltd (002382)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Blue Sail Medical Co Ltd it is ¥4.42 per share (as of Oct 3, 2026), against a price of ¥6.29. It is the blended result of 4 valuation models (cash flow, earnings, asset, dividend).
Is Blue Sail Medical Co Ltd stock overvalued or undervalued in 2026?
As of Oct 3, 2026, 002382 trades above its calculated fair value: price ¥6.29, fair value ¥4.42, a gap of about −30% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 002382?
No. The price is what the market pays today (¥6.29); the fair value is what the company's own numbers justify (¥4.42). For Blue Sail Medical Co Ltd the two are ¥1.87 per share apart. That gap is exactly why we show both numbers side by side.
How much is Blue Sail Medical Co Ltd worth?
The market values Blue Sail Medical Co Ltd at about 6.3B CNY (market capitalisation, as of Oct 3, 2026). Per share that is ¥6.29; our models calculate a fair value of ¥4.42 per share.
What do the bullish and bearish scenarios say about 002382?
Our models span a range for Blue Sail Medical Co Ltd: cautious scenario ¥3.02, base ¥4.42, optimistic ¥5.82 per share (as of Oct 3, 2026, price ¥6.29). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Blue Sail Medical Co Ltd (002382)?
Balance-sheet figures for Blue Sail Medical Co Ltd (as of Oct 3, 2026): return on equity −4.9%, debt of 0.09 per unit of equity. They feed the Quality Score of 41/100, which measures business quality independently of the share price.
How far is 002382 from its 52-week high?
Blue Sail Medical Co Ltd trades at ¥6.29, about 27% below its 52-week high of ¥8.66 and 24% above the low of ¥5.08 (as of Oct 19, 2026). Distance from the high says nothing about value: that is what the fair value of ¥4.42 is for.
Which stocks are comparable to Blue Sail Medical Co Ltd?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Blue Sail Medical Co Ltd stock attractive at the current price?
The data as of Oct 3, 2026: price ¥6.29, calculated fair value ¥4.42 (−30%), Quality Score 41/100, from 4 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 002382 calculated?
We run Blue Sail Medical Co Ltd through 4 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥4.42, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.9 % above its aggregate fair value. Blue Sail Medical Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Blue Sail Medical Co Ltd (002382)?
The closing price on Oct 19, 2026 was ¥6.29. Our model-based fair value is ¥4.42, about −30% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Blue Sail Medical Co Ltd right now?
The price sits above even our optimistic bull case (¥5.82). The favourable scenario is already priced in. Weak quality (41/100) and above fair value at the same time, the margin of safety is missing on both counts. A fairly wide model range (¥3.02 to ¥5.82) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Blue Sail Medical Co Ltd

How large is the market capitalisation of Blue Sail Medical Co Ltd (002382)?
The market capitalisation of Blue Sail Medical Co Ltd is 6.3B CNY (≈ $950M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Blue Sail Medical Co Ltd (002382)?
The price-to-sales ratio of Blue Sail Medical Co Ltd is 0.97 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Blue Sail Medical Co Ltd (002382)?
Earnings per share at Blue Sail Medical Co Ltd are ¥−0.5400. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Blue Sail Medical Co Ltd (002382)?
The dividend yield of Blue Sail Medical Co Ltd is 2.6%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Blue Sail Medical Co Ltd (002382)?
The net margin of Blue Sail Medical Co Ltd is −8.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Blue Sail Medical Co Ltd (002382)?
The return on equity (ROE) of Blue Sail Medical Co Ltd is −4.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Blue Sail Medical Co Ltd (002382)?
On an EBIT basis the return on assets of Blue Sail Medical Co Ltd is −0.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Blue Sail Medical Co Ltd (002382)?
The operating margin of Blue Sail Medical Co Ltd is 17.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Blue Sail Medical Co Ltd (002382)?
Revenue at Blue Sail Medical Co Ltd is growing +56.5% versus a year earlier (3y avg +5.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Blue Sail Medical Co Ltd (002382)?
Earnings per share at Blue Sail Medical Co Ltd are growing −98.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Blue Sail Medical Co Ltd (002382) generate?
The free cash flow of Blue Sail Medical Co Ltd is −95.3M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Blue Sail Medical Co Ltd (002382) carry?
The net debt of Blue Sail Medical Co Ltd is 1.2B CNY (fiscal year 2024). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Blue Sail Medical Co Ltd in the live analysis

One click puts Blue Sail Medical Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.